Cancer-related anaemia

Krzysztof Gawrychowski

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

6/2006
vol. 10

Send email

Copy url:

abstract:

Cancer-related anaemia

Krzysztof Gawrychowski

Współcz Onkol 2006, 6, 310-312

Online publish date: 2006/08/16

View full text Get citation

Cancer-related anaemia occurs during the underlying malignancy in 40-75 percent of the patients. It has the influence on the quality of life, which can be significantly reduced and on the results of the planned and undergoing treatment. The mild anaemia can negatively impact the therapeutic treatment. Anaemia is often exacerbated by cancer treatment- -chemotherapy and radiotherapy. The blood transfusions or erythropoietin therapy help to equalize the decreased level of haemoglobin. Particular attention must be paid to the patients who received myelosuppressive treatment, radiation (in the pelvis minor area) and in cases when after the first course of chemotherapy the level of haemoglobin decreased by 2 g/dl. Numerous clinical studies have shown that erythropoietin can be an effective treatment in cancer-related anaemia.

keywords:

Cancer-related anaemia

Krzysztof Gawrychowski

chemotherapy, treatment of anaemia, erythropoietin, darbepoetin